Article: Optofluidics Technology Accelerates Discovery of Covid-19 Treatments
Read this Science Advisory Board article by Samantha Black, Ph.D., about the rapid impact of the Beacon® optofluidic system during the early days of the COVID-19 pandemic.
SAB-Article_Immunology_R1
Access the original article.
Related Resources
View All ResourcesBrochure: Cell Line Development
Find out how the Opto™ CLD workflow lets you generate the best production cell lines for complex antibody therapeutics with >99% monoclonality assurance in just days.
Cell Line Development Webinar: Digital Week 2019
Learn about improved and expedited cell line development on the Beacon platform from Biogen’s Rachel Ferguson.
Poster: Rapid Generation of Production Cell Lines with Superior Titers and >99% Monoclonality for Complex Antibody Molecules
See how the Opto CLD 2.0 Workflow enables rapid generation of cell lines secreting antibodies for both traditional and non-traditional antibodies while acquiring a superior data package.